Navidea Biopharmaceuticals Announces the Presentation of Lymphoseek Data at Upcoming Scientific Meetings

Data from Lymphoseek studies to be presented at the Radiological Society of North America Conference (RSNA) and the San Antonio Breast Cancer Symposium

DUBLIN, Ohio--(BUSINESS WIRE)--Nov 26, 2012 - Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that data from its Lymphoseek® (technetium Tc 99m tilmanocept) studies in breast cancer and melanoma are being presented during the Radiological Society of North America Conference (RSNA) in Chicago and the CTRC-AACR San Antonio Breast Cancer Symposium in San Antonio, Texas. Details of the poster presentations are listed below.

       
Conference:

 

    Radiological Society of North America Conference (RSNA)

 

Date:

 

    November 25-30, 2012

 

Location:

 

    Chicago

 

       
Poster Title 1:

 

    In Phase 3 Clinical Studies in Melanoma and Breast Cancer, Receptor-Targeted (CD206) Tc 99m Tilmanocept Provided Enhanced Intraoperative Lymphatic Mapping, Leading to Increased Pathology Findings in Patients and Upstaging in Pathology-Positive Patient

 

Author:

 

    Frederick Cope, Ph.D., Navidea Biopharmaceuticals

 

Session, Date:

 

    Poster Sessions, Monday, Nov. 26, 2012, 12:15 – 12:45 p.m.

 

       
Poster Title 2:

 

    A Phase 3 Clinical Trial Employing Tc 99m Tilmanocept, a Novel CD206-Targeted Intraoperative Lymphatic Mapping Agent For Breast Cancer and Melanoma, Shows Significant Concordance between Preoperative Imaging and Intraoperative Localization of Disease

 

Author:

 

    Frederick Cope, Ph.D., Navidea Biopharmaceuticals

 

Session, Date:

 

    Poster Sessions, Wednesday, Nov. 28, 2012, 12:45 – 1:15 p.m.

 

       
Conference:

 

    CTRC-AACR San Antonio Breast Cancer Symposium

 

Date:

 

    December 4-8, 2012

 

Location:

 

    San Antonio, Texas

 

       
Poster Title:

 

    Tc 99m Tilmanocept and Sulfur Colloid Injection: A comparison of Preoperative Imaging and Intraoperative Lymphatic Mapping of Breast Cancer Patients – Localization Rate and Degree of Localization

 

Author:

 

    Frederick Cope, Ph.D., Navidea Biopharmaceuticals

 

Session, Date:

 

    Poster Session 1, Wednesday, Dec. 5, 2012, 5 – 7 p.m.

 

       
About Lymphoseek®

Lymphoseek® (technetium Tc 99m tilmanocept) Injection is a novel, receptor-targeted, small-molecule, investigational radiopharmaceutical used in lymphatic mapping procedures that are performed to help stage cancers such as breast cancer and melanoma. Lymphoseek is designed to identify the lymph nodes that drain from a primary tumor, which have the highest probability of harboring cancer.

Lymphatic mapping is a procedure in which lymph nodes that may contain tumor metastases are identified and biopsied to determine if cancer has spread beyond the primary tumor. Accurate staging of cancer is critical, as it guides therapy decisions and determines patient prognosis and risk of recurrence. According to the American Cancer Society, approximately 229,000 new cases of breast cancer and 76,000 new cases of melanoma are expected to be diagnosed in the United States in 2012.

About Navidea Biopharmaceuticals, Inc.

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents. Navidea is actively developing four radiopharmaceutical agent platforms – Lymphoseek®, NAV4694, NAV5001 and RIGScanTM – to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making and, ultimately, patient care. Navidea's strategy is to deliver superior growth and shareholder return by bringing to market novel radiopharmaceutical agents and advancing the Company's pipeline through selective acquisitions, global partnering and commercialization efforts. For more information, please visit www.navidea.com.

The Private Securities Litigation Reform Act of 1995 (the Act) provides a safe harbor for forward-looking statements made by or on behalf of the Company. Statements in this news release, which relate to other than strictly historical facts, such as statements about the Company's plans and strategies, expectations for future financial performance, new and existing products and technologies, anticipated clinical and regulatory pathways, and markets for the Company's products are forward-looking statements within the meaning of the Act. The words “believe,” “expect,” “anticipate,” “estimate,” “project,” and similar expressions identify forward-looking statements that speak only as of the date hereof. Investors are cautioned that such statements involve risks and uncertainties that could cause actual results to differ materially from historical or anticipated results due to many factors including, but not limited to, the Company's continuing operating losses, uncertainty of market acceptance of its products, reliance on third party manufacturers, accumulated deficit, future capital needs, uncertainty of capital funding, dependence on limited product line and distribution channels, competition, limited marketing and manufacturing experience, risks of development of new products, regulatory risks and other risks detailed in the Company's most recent Annual Report on Form 10-K and other Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements.

 

Contact: Navidea Biopharmaceuticals, Inc.
Brent Larson, 614-822-2330
Sr. VP & CFO

 

 

Posted: November 2012

View comments

Hide
(web4)